Peptides for fertility and reproductive health — beyond IVF

Fertility is where reproductive biology becomes inescapably personal, and where the stakes of getting the medicine right — or at least well-informed — are unusually high.

The biology of human reproduction involves a layered hormonal cascade that is precise in ways that are easy to underestimate. At the top is the hypothalamus, which releases gonadotropin-releasing hormone — GnRH — in pulses, not continuously. Pulsatility matters here more than almost anywhere else in endocrinology: GnRH released in pulses of the right frequency and amplitude drives the pituitary to produce LH and FSH; GnRH delivered continuously, paradoxically, suppresses pituitary function by desensitizing GnRH receptors. The pituitary then produces LH and FSH, which act on the ovaries to drive follicle development and ovulation. In men, LH drives testosterone production from Leydig cells and FSH drives spermatogenesis in Sertoli cells. The elegance of the pulse-dependent system has direct clinical implications, both for how it can fail and for how it can be therapeutically supported.

Anovulation — the failure to ovulate — is the most common cause of female infertility and comes in several biologically distinct patterns. Polycystic ovarian syndrome accounts for a large proportion, involving both insulin resistance and LH hypersecretion that disrupts follicle maturation and ovulation. Hypothalamic amenorrhea — the functional shutdown of the HPO axis from energy deficit, excessive exercise, or psychological stress — involves suppressed GnRH pulsatility at the top of the cascade. Premature ovarian insufficiency represents failure at the ovary level. Each pattern has different implications for what interventions are meaningful.

Male factor infertility — low sperm count, poor motility, abnormal morphology — contributes to roughly half of infertility cases when evaluated comprehensively, either as a primary cause or a contributing factor. It is significantly underinvestigated relative to its prevalence; the instinct to start the evaluation with the female partner delays diagnosis and appropriate intervention. Secondary hypogonadism in men — where testosterone is low because the pituitary is not signaling adequately — is both a cause of infertility and a condition that is worsened by testosterone replacement therapy, which suppresses the gonadotropin signaling that drives spermatogenesis.

Unexplained infertility, by definition, is the category where standard investigation hasn't found a clear cause. It doesn't mean nothing is wrong — it means the evaluation hasn't identified what's wrong — and the biology of implantation, endometrial receptivity, embryo quality, and immune factors at the implantation interface is not captured by standard semen analysis plus ovulation confirmation plus HSG.

The conventional management hierarchy moves in a defined order for most presentations. Lifestyle and timing optimization first: weight normalization if indicated (both underweight and overweight affect fertility through different mechanisms), discontinuing substances that impair sperm or egg quality, confirming ovulation and timing intercourse appropriately, both-partner evaluation. Ovulation induction second: clomiphene citrate (which blocks estrogen receptors in the hypothalamus, causing a compensatory rise in gonadotropins) and letrozole (which lowers estrogen via aromatase inhibition, similarly driving gonadotropin rise) are first-line for ovulatory dysfunction, letrozole now preferred in PCOS based on trial data. Gonadotropins — injectable FSH, either alone or with LH activity (HMG) — provide more direct stimulation and are used when oral agents fail. IUI adds insemination at the ovulation window. IVF represents the step where follicle development, egg retrieval, fertilization, and embryo transfer are brought under direct control; ICSI addresses severe male factor by directly injecting sperm into eggs.

Now for the peptide threads running through this landscape — and they are significant, because fertility medicine has worked with peptides longer and more directly than almost any other specialty.

HCG — human chorionic gonadotropin — is a naturally occurring peptide hormone produced by the developing embryo and placenta, and also an LH analog used pharmacologically throughout fertility medicine. It is used to trigger final oocyte maturation and ovulation in stimulated cycles — the "trigger shot" that precedes IUI and egg retrieval in IVF. It supports the corpus luteum during the luteal phase after ovulation. In men with secondary hypogonadism and infertility, HCG maintains testicular function by substituting for LH, driving testosterone production and supporting spermatogenesis — making it the critical alternative to testosterone replacement when fertility preservation matters. In men who have suppressed their gonadotropin axis through prolonged testosterone replacement therapy, HCG is used in post-cycle recovery protocols to restore testicular function. HCG has FDA-approved indications and is used routinely by reproductive endocrinologists; the compounded HCG landscape has changed following FDA regulatory action that restricted compounded HCG formulations in the United States, making the pharmacy and sourcing question especially important to navigate with a prescribing provider.

Gonadorelin — synthetic GnRH — has historically been used for pulsatile replacement in patients with hypogonadotropic hypogonadism, where the hypothalamus is not producing adequate GnRH. Pulsatile gonadorelin delivered via pump mimics endogenous GnRH pulsatility with impressive physiological fidelity — the pituitary responds as it would to natural GnRH, and the downstream HPO axis activation supports ovulation and fertility. This application is particularly important in hypothalamic amenorrhea, where the failure is at the GnRH level and exogenous gonadotropins can bypass the axis entirely but pulsatile gonadorelin restores the system's own function. Gonadorelin's regulatory status in the United States has become complicated — it was previously available as Factrel and Lutrepulse for pulsatile use, but marketed formulations have changed, and current compounded use is largely off-label. The mechanism is well-established, but navigating the current prescribing landscape requires an experienced reproductive endocrinologist.

Cetrorelix and ganirelix are GnRH antagonists — they bind GnRH receptors and block the pituitary's response to GnRH, suppressing LH and preventing premature ovulation during stimulated IVF cycles. They are FDA-approved and routinely used in IVF protocols. They are the mechanistic opposite of gonadorelin in their effect on the system but serve a critical role in cycle control. Understanding where they fit helps frame why the upstream GnRH axis is so central to reproductive pharmacology.

Kisspeptin-10 represents an emerging and genuinely interesting area of research. Kisspeptin is a neuropeptide produced in the hypothalamus that acts as the critical upstream regulator of GnRH release — it is, in a sense, the master switch for the reproductive axis. Kisspeptin neurons integrate signals from energy status, circadian rhythm, stress, and other systemic factors to decide whether the GnRH pulse generator should run or be suppressed. In functional hypothalamic amenorrhea, the kisspeptin signal is suppressed — the energy or stress burden convinces the system to shut down reproductive function. Research has explored kisspeptin-10 administration for ovulation triggering in IVF cycles as an alternative to HCG (with a potentially lower risk of ovarian hyperstimulation syndrome), and for stimulating endogenous LH surges in fertility preservation contexts. Off-label interest in kisspeptin-10 for supporting HPO axis function in hypothalamic amenorrhea and for upstream fertility support has grown in some functional reproductive medicine practices. The research is promising but incomplete; kisspeptin-10 is not FDA-approved for fertility indications, and use in this context is investigational and requires specialist oversight.

The intersection of general wellness peptide protocols with fertility planning requires a careful and non-negotiable conversation about discontinuation. Many peptides that may be appropriate for other health goals have either unknown effects in pregnancy or actively concerning ones. BPC-157 has not been studied in human pregnancy; animal safety data is insufficient to justify use in a person attempting conception. GH-axis peptides — sermorelin, ipamorelin, CJC-1295 — have no established safety in pregnancy and should be discontinued before and during attempted conception. GLP-1 agonists are currently recommended to be discontinued before conception, as their effects on placental development and fetal outcomes are not adequately characterized. The practical implication: anyone on a peptide protocol who is planning to attempt pregnancy needs to work with their prescribing provider to map which compounds should be stopped, when, and what the washout timeline looks like.

This is not a minor caveat. It is the non-negotiable framing for any peptide conversation in the fertility context.

The preconception optimization picture deserves specific attention because the foundational work here has evidence behind it that exceeds almost any intervention at the margin. For both partners, this means weight within a healthy range — both obesity and significant underweight affect hormonal function and gamete quality. Alcohol reduction or elimination — even moderate alcohol affects sperm parameters and has effects on ovulation and early embryo development. Folate (or methylfolate in those with MTHFR variants) before conception, because neural tube closure occurs before most people know they're pregnant. Vitamin D adequacy. Sleep. Stress — the kisspeptin-hypothalamic amenorrhea connection is a direct mechanistic link between psychological and physical stress and reproductive suppression. Tobacco cessation, which has pronounced effects on ovarian reserve, sperm DNA fragmentation, and implantation.

None of these are glamorous. They are also more consistently supported by the evidence than anything at the research margin.

Recurrent pregnancy loss — typically defined as two or more pregnancy losses — has a distinct evaluation pathway that includes chromosomal analysis of both partners, uterine anatomy assessment, thrombophilia workup, hormonal evaluation, and sometimes immunological assessment. The immunological dimension of some recurrent loss cases — involving natural killer cell activity, HLA compatibility questions, and implantation immune factors — has generated interest in immunomodulatory approaches, and this is an area where some reproductive immunologists work with compounds including IVIG, intralipid, and sometimes regulatory immune peptides. This is highly specialized territory, not a starting point for self-directed protocols.

Fertility is reproductive endocrinology specialist territory, and the specialist matters. A reproductive endocrinologist brings both the diagnostic precision to understand which biological failure is actually driving the problem and the clinical experience to know which interventions have a reasonable evidence base for that specific problem. The growing interest in peptide approaches to fertility — gonadorelin for HPO axis support, kisspeptin-10 for upstream regulation, HCG for male factor and luteal support — exists within that specialist context, not outside it.

The hope that goes into fertility medicine is enormous. The stakes make it a field where the temptation to reach for anything that might help is understandable, and where that same urgency makes careful evaluation more important, not less. Understanding which peptides are FDA-approved and standard-of-care in reproductive medicine, which are being actively researched, and which require careful individual assessment before any use — and which must unambiguously be stopped before attempting conception — is the foundation for that careful evaluation.